NextCure to Merge with Avere Therapeutics in All-Stock Deal, Secures $320M PIPE, and Restructures Operations
NXTC has more than doubled off its 52-week low of $1.55 on elevated volume (2.2× avg).
Summary
NextCure is merging with Avere Therapeutics in a deal that will give legacy NextCure stockholders only ~1.89% of the combined company. A $320M PIPE and a restructuring accompany the merger, marking a complete strategic pivot.
Key Events · M&A and Partnerships · NXTC
-
Reverse Merger with Avere Therapeutics
NextCure will merge with private biotech Avere Therapeutics in an all-stock deal. Pre-merger Avere stockholders will own ~98.11% of the combined company, while legacy NextCure stockholders will own ~1.89%.
-
$320M Private Placement
Avere concurrently raised $320 million from a syndicate including Fairmount, Hansoh, Venrock, and others. The financing includes $251 million of convertible notes that will convert at closing.
-
Contingent Value Rights for Legacy Assets
NextCure stockholders will receive one CVR per share, entitling them to 90% of net proceeds from any future monetization of NextCure's legacy pipeline assets over a two-year period.
-
Workforce Reduction and Program Halts
NextCure approved a restructuring plan to lay off a substantial majority of its workforce, with ~$1.9 million in charges. It also halted expansion of the SIM0505 program and opted out of cost-sharing for LNCB74.
Analysis · NXTC · Life Sciences
NextCure is merging with private biotech Avere Therapeutics in a reverse merger that will leave legacy NextCure stockholders with only about 1.89% of the combined company. Avere's lead asset is an oral IL-23 receptor antagonist with Phase 1b data. A concurrent $320 million private placement from a blue-chip investor syndicate will fund operations through Phase 2b readouts. NextCure is also halting expansion of its own clinical programs and laying off most of its workforce, signaling a complete strategic pivot. The deal includes a contingent value right for NextCure stockholders to receive 90% of net proceeds from any future monetization of legacy assets, but there is no guarantee of any payout.
At the time of this filing, NXTC was trading at $8.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.